Expression of TOPK/PBK in children with malignant lymphoma or reactive lymphoid hyperplasia.
- Author:
Xin TIAN
1
;
Xiang-Ling HE
;
Xiao-Ye YUAN
;
Run-Ying ZOU
;
Hui ZOU
;
Ya-Lan YOU
;
Ke-Ke CHEN
;
Cheng-Guang ZHU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Lymph Nodes; enzymology; Lymphoma; enzymology; Mitogen-Activated Protein Kinase Kinases; analysis; Pseudolymphoma; enzymology
- From: Chinese Journal of Contemporary Pediatrics 2018;20(3):214-217
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the difference in expression of TOPK/PBK in lymph nodes between children with malignant lymphoma and those with reactive lymphoid hyperplasia.
METHODSEighty children with malignant lymphoma and twenty children with reactive lymphoid hyperplasia were enrolled as subjects. Immunohistochemistry was used to determine the expression of TOPK/PBK in all the subjects. The expression of TOPK/PBK was compared between the two groups.
RESULTSThe TOPK/PBK-positivity rate was significantly higher in children with malignant lymphoma than in those with reactive lymphoid hyperplasia (P<0.05). There was no significant difference in the TOPK/PBK-positivity rate between the children with Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL). There were significant differences in the TOPK/PBK-positivity rate among children with different pathological types of NHL (P<0.05): the children with lymphoblastic lymphoma showed the highest TOPK/PBK-positivity rate and those with mature B-cell lymphoma and mature T/NK-cell lymphoma had a similar TOPK/PBK-positivity rate.
CONCLUSIONSThe expression of TOPK/PBK is up-regulated in the lymph nodes of children with malignant lymphoma. The expression level of TOPK/PBK may be related to the pathological type of NHL.
